Biocryst pharmaceuticals inc (BCRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities
Net loss

-115,442

-108,897

-133,707

-125,712

-106,529

-101,252

-93,363

-78,900

-77,340

-65,782

-50,742

-47,136

-46,531

-55,144

-68,776

-71,869

-50,687

-43,019

-36,556

-30,666

-50,216

-45,189

-38,946

-38,216

-35,739

-30,108

-35,732

-37,431

-37,535

-39,081

-41,220

-45,978

-49,973

-56,948

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

766

724

737

750

760

770

754

737

718

704

694

691

608

483

354

222

182

180

177

174

169

177

194

218

260

304

414

486

557

628

717

766

829

886

0

0

0

Stock-based compensation expense

17,156

17,719

16,355

13,111

9,810

9,396

9,386

12,820

13,062

12,621

12,316

8,784

8,304

8,487

8,410

8,262

10,091

9,705

11,400

10,982

10,826

10,177

7,439

6,976

4,376

4,368

4,301

4,510

4,725

4,167

4,245

4,222

4,349

4,772

0

0

0

Amortization of debt issuance costs

1,364

1,278

1,145

1,026

908

885

894

892

888

876

881

777

668

558

445

439

439

439

439

439

439

439

439

439

439

439

439

439

439

439

439

439

435

356

0

0

0

Amortization of premium/discount on investments

183

117

-41

-47

-28

110

184

211

215

157

149

307

308

523

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of foreign currency derivative

-773

-347

-975

-510

1,161

-1,049

286

-208

-1,227

-966

6,325

5,309

2,021

811

-7,143

-6,673

-3,781

-564

3,962

8,505

7,477

5,487

2,858

5,015

1,810

5,294

3,950

-2,861

1,171

-749

-2,605

-2,619

-2,620

-4,000

0

0

0

Deferred revenue

0

-

-

-

-

-

-

-

-

-1,722

-1,780

-1,601

-1,600

-1,631

-1,478

-5,548

1,078

1,199

6,911

10,832

4,366

4,429

-1,242

-1,239

-1,247

-1,103

-952

-3,719

-2,048

-9,577

-9,919

-7,432

-8,609

-1,552

0

0

0

Changes in operating assets and liabilities:
Receivables

640

17,853

204

1,260

-692

-1,824

-5,591

-983

-3,870

-2,651

3,017

1,091

2,180

2,525

-1,527

-2,062

1,790

-3,247

4,257

3,399

2,314

7,375

869

-7,203

-1,045

-2,447

-1,399

3,016

-1,528

-1,269

-7,866

-10,877

-20,209

-24,396

0

0

0

Inventory

-

-

-

-

-

1,649

821

-1,084

-648

-500

-2,232

-644

-1,294

-1,112

2,232

641

739

929

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

3,581

1,364

821

435

-1,519

866

129

-691

-220

-951

-3,052

-2,615

-3,964

-3,702

-432

-1,134

1,757

-637

1,192

1,182

1,137

2,093

90

1,081

-951

620

789

675

1,317

623

-23

14

-312

-626

0

0

0

Deferred collaboration expense

-

-

-

-

-

-

-

-

-

-

-79

-69

-70

-71

-58

-71

97

102

103

107

-58

-59

-58

-10,269

-5,053

-5,133

-5,221

4,789

-446

-2,301

-2,354

-2,316

-2,429

-1,309

0

0

0

Accounts payable and accrued expenses

8,070

11,741

10,515

2,619

2,906

4,487

6,486

9,264

2,352

3,842

2,845

-2,757

-8,341

-10,524

-10,972

-3,678

9,731

13,676

13,636

13,515

10,312

4,656

6,478

4,776

2,813

-2,049

922

-2,429

-2,254

2,068

-4,758

-5,275

-7,201

-10,731

0

0

0

Interest payable

2,989

3,056

2,996

-87

-73

-247

-278

3,245

3,174

3,105

3,142

2,384

2,317

2,244

2,046

4,753

733

717

693

664

2,689

2,162

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Interest reserve

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in operating activities

-85,867

-89,584

-103,121

-110,516

-99,910

-92,565

-79,099

-56,497

-52,269

-41,143

-36,478

-41,606

-43,123

-53,438

-62,412

-57,514

-28,232

-13,116

-12,178

-8,118

-33,318

-38,551

-29,176

-28,498

-24,291

-26,530

-29,045

-32,900

-36,347

-37,397

-34,351

-33,043

-30,172

-32,251

0

0

0

Investing activities
Acquisition of property and equipment

366

343

367

325

424

366

377

525

360

328

212

202

2,020

5,277

9,324

9,287

7,817

5,122

1,141

1,033

664

106

0

0

0

-

-

-

-

113

116

111

94

55

0

0

0

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-116

2,857

-672

1,462

1,472

1,419

2,487

-1

0

-1,979

-466

-157

-150

-101

-339

-317

0

0

0

-

-

-

-

Purchases of investments

-

3,018

22,474

48,878

61,305

62,614

111,373

91,471

112,114

107,787

0

0

0

-

-

-

-

53,830

106,366

80,631

67,886

73,875

0

0

0

-

-

-

-

16,153

23,219

32,358

44,675

45,500

0

0

0

Sales and maturities of investments

73,143

81,295

81,347

74,670

66,451

67,748

62,289

54,023

49,614

43,461

36,907

47,461

50,468

42,652

44,808

36,590

46,248

42,410

40,874

37,984

28,132

34,000

35,485

34,410

26,300

20,330

19,163

21,842

27,608

40,833

41,556

56,495

60,198

56,873

0

0

0

Net cash provided by investing activities

72,777

77,934

58,506

25,467

4,722

4,768

-49,449

-37,961

-62,848

-64,642

-17,085

2,901

34,699

23,273

30,113

-9,977

-11,349

-18,004

-68,105

-45,099

-42,905

-39,980

10,846

172

-6,562

-3,467

2,441

19,925

15,416

24,884

18,546

23,212

15,099

11,318

0

0

0

Financing activities
Proceeds from senior credit facility

-

19,477

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of common stock, net

-

-

-

-

-

-

-

-

-

134,000

0

0

47,750

-

-1,175

-1,175

-1,175

0

0

0

0

-

-

-

-

23,633

23,642

7,637

6,487

17,805

0

0

0

-

-

-

-

Net proceeds from common stock issued under stock-based compensation plans

942

1,239

2,518

3,093

3,147

2,852

1,585

1,249

899

1,581

1,604

1,352

1,260

317

1,466

1,942

5,160

5,479

4,888

4,732

1,829

5,307

4,652

5,132

5,035

1,333

1,329

370

127

534

560

550

647

278

0

0

0

Payment of senior credit facility

-

-

-

-

-

4,025

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) increase in lease financing obligation

-

-

-

-

-

-76

-73

85

103

122

168

115

198

329

300

214

131

0

-310

-128

-128

0

310

184

184

124

124

241

241

321

321

278

278

300

0

0

0

Receipt of foreign currency derivative collateral

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-300

1,140

5,180

-7,000

-410

400

-1,700

-4,470

-4,440

-4,970

-3,480

0

0

0

Purchases of treasury stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

61

0

0

0

Issuance of non-recourse notes payable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25,691

0

0

0

Net cash provided by financing activities

79,324

99,098

21,975

85,709

84,020

62,504

61,740

84,134

85,527

135,703

137,462

73,485

71,866

23,304

21,059

-629

4,116

5,479

5,753

8,479

111,006

111,907

113,437

130,078

29,632

30,270

28,695

10,818

8,075

16,960

17,323

14,747

11,392

23,755

0

0

0

Increase (decrease) in cash, cash equivalents and restricted cash

66,234

87,448

-22,640

660

-11,168

-25,293

-66,808

-10,324

-29,590

29,918

83,899

34,780

63,442

-6,861

-11,240

-68,120

-35,465

-25,641

-74,530

-44,738

34,783

33,376

95,107

101,752

-1,221

273

2,091

-2,157

-12,856

4,447

1,518

4,916

-3,681

2,822

0

0

0